Press Room

AAPS 2018

Start
Sunday, November 04, 2018 - 00:00
End
Wednesday, November 07, 2018 - 00:00
Location: Washington DC, United States
Booth Number: 2309
Spray Drying Development by Design | Hovione

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Adam Neunuebel will be pleased to meet you.

adam-neunuebel-photo

Adam Neunuebel

Head of Business Development

 

HOVIONE POSTERS

Poster name / Presentation Authors / Presenter Poster # and Presenter Presentation  Date / Time
Use of Hot Melt Extrusion for the production of controlled release diclofenac formulation with PLGA/PLA - standard and accelerated IVR methods João Henriques #M1030-07-056 - João Henriques Monday, Nov 5

10:30 – 11:30 
Microfludization for Solubility Enhancement – One Technology Fits All Fonseca, T., Duarte, I., Vicente, J.,

Temtem, M
#M1430-10-075 - Iris Duarte Monday, Nov 5

14:30 – 15:30 
Performance evaluation during process development: different techniques, complementary results Luis Sousa #M1530-07-049 - Luis Sousa Monday, Nov 5

15:30 – 16:30 
Identify your limits: definition of Spray drying Tout based on a novel methodology to measure powder stickiness  Luis Sousa #T1130-07-050 - Luis Sousa Tuesday, Nov 6

11:30 – 12:30 
Laser diffraction analysis of supersaturated solutions and application to screening of amorphous dispersions  Luis Sousa #T1230-07-049 - Luis Sousa Tuesday, Nov 6

12:30 – 13:30 
Effect of Surfactant Level on Properties of Celecoxib Amorphous Solid Dispersion  Fan Meng, Rui Ferreira,

Feng Zhang
#T1330-09-065  Tuesday, Nov 6

13:30 – 14:30 
Miniaturized methodology of polymer screening for spray dried dispersions  Luis Sousa #W0930-07-050 - Luis Sousa Wednesday, Nov 7

9:30 – 10:30 
New formulation screening approach to optimize tablet disintegration profiles based on cloud/precipitation point measurement João Henriques #W1030-13-097 - João Henriques Wednesday, Nov 7

10:30 – 11:30 
How to develop an amorphous solid dispersion in tablets with less than 30 g API João Henriques #W1030-13-100 - João Henriques Wednesday, Nov 7

10:30 – 11:30 
DPI Carrier-Based Formulation Scale-Up: A Statistical Analysis Approach Marcio Temtem, Filipa Maia,

Isabel Lopes, Luis Sousa,

Maria Braga, Nuno Neves
#W1230-09-068 - Eunice Costa  Wednesday, Nov 7

12:30 – 13:30 
Simulating the Pulmonary Route: From Actuation to Absoption Beatriz Fernandes, Maria Malmlof,

Marcio Temtem,

M. Luisa Corvo,

Per Gerde, Eunice Costa
#W1230-09-065  Wednesday, Nov 7

12:30 – 13:30 
Molecular Interactions between Rafoxanide and Povidone for Amorphous Solid Dispersion Preparation and Feng Zhang. Fan Meng, Zhifeng Jing,

Yongchao Su, Rui Ferreira, Pengyu Ren 
   

 

 

 

 

 

 

 

 

 

 

 

 

 

You might be also interested in

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026